Emerging gene-directed anti-tumor strategies against human hepatoblastoma

Bibliography

• Ishak KG. Primary hepatic tumors in childhood. Prog Liver Dis 1976;5:636-67
   PubMedGoogle Scholar
• Ross JA, Gurney JG. Hepatoblastoma incidence in the United States from 1973 to 1992. Med Pediatr Oncol 1998;30:141-2
   PubMedGoogle Scholar
• Ishak KG, Glunz PR. Hepatoblastoma and hepatocarcinoma in infancy and childhood. Report of 47 cases. Cancer 1967;20:396-422
   PubMed Web of Science ®Google Scholar
• Stiller CA, Pritchard J, Steliarova-Foucher E. Liver cancer in European children: incidence and survival, 1978-1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer 2006;42:2115-23
   PubMed Web of Science ®Google Scholar
• Litten JB, Tomlinson GE. Liver tumors in children. Oncologist 2008;13:812-20
   PubMed Web of Science ®Google Scholar
• Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a Pediatrc Oncology Group Phase II study. J Clin Oncol 2002;20:3438-44
   PubMed Web of Science ®Google Scholar
• Fuchs J, Rydzynski J, von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer 2002;92:172-82
   Web of Science ®Google Scholar
• Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. Final report of the second study of the International Society of Paediatric Oncology–SIOPEL 2. Eur J Cancer 2004;40:411-21
   PubMed Web of Science ®Google Scholar
• Mildenberger H, Bürger D, Weinel P. Das Hepatoblastom: eine katamnestische untersuchung und vorschlag eines therapiekonzeptes. Z Kinderchir 1989;44:78-82
   PubMedGoogle Scholar
• Reynolds M. Conversion of unresectable to resectable hepatoblastoma and long-term follow-up study. World J Surg 1995;19:814-816
   PubMed Web of Science ®Google Scholar
• Von Schweinitz D, Byrd DJ, Hecker H, et al. Efficiency and toxicity of ifosfamide, cisplatin and doxorubicin in the treatment of childhood hepatoblastoma. Study Committee of the Cooperative Liver Tumor Study HB89 of the German Society of Pediatric Hematology and Oncology. Eur J Cancer 1997;33:1243-49
   PubMed Web of Science ®Google Scholar
• Lockwood L, Heney D, Giles GR, et al. Cisplatin-resistant metastatic hepatoblastoma: complete response to carboplatin, etoposide, and liver transplantation. Med Pediatr Oncol 1993;21:517-20
   PubMedGoogle Scholar
• Von Schweinitz D, Hecker H, Harms D, et al. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma–a report from the German Cooperative Pediatric Liver Tumor Study HB-89. J Pediatr Surg 1995;30:845-52
   PubMed Web of Science ®Google Scholar
• Warmann S, Göhring G, Teichmann B, et al. P-glycoprotein modulation improves in vitro chemosensitivity in malignant pediatric liver tumors. Anticancer Res 2003;23:4607-11
   PubMed Web of Science ®Google Scholar
• Warmann S, Hunger M, Teichmann B, et al. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer 2002;95:1795-801
   PubMed Web of Science ®Google Scholar
• Warman SW, Fuchs J. Drug resistance in hepatoblastoma. Curr Pharm Biotechnol 2007;8:93-7
   PubMed Web of Science ®Google Scholar
• Eichenmüller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology 2009;49:482-90
   PubMed Web of Science ®Google Scholar
• Kingston JE, Herbert A, Draper GJ, et al. Association between hepatoblastoma and polyposis coli. Arch Dis Child 1983;58:959-62
   PubMed Web of Science ®Google Scholar
• DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from the Beckwith-Wiedemann Syndrome Registry. J Pediatr 1998;132:398-400
   PubMed Web of Science ®Google Scholar
• Rainier S, Dobry CY, Feinberg AP. Loss of imprinting in hepatoblastoma. Cancer Res 1995;55:1836-8
   PubMed Web of Science ®Google Scholar
• Honda S, Arai Y, Haruta M, et al. Loss of imprinting of IGF2 correlates with hypermethylation of the H19 differentially methylated region in hepatoblastoma. Br J Cancer 2008;99:1891-9
   PubMed Web of Science ®Google Scholar
• Park WS, Oh RR, Park YS, et al. Nuclear localization of β-catenin is an important prognostic factor in hepatoblastoma. J Pathol 2001;193:483-90
   PubMed Web of Science ®Google Scholar
• Monga SP, Mars WM, Pediaditakis P, et al. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res 2002;62:2064-71
   PubMed Web of Science ®Google Scholar
• Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastoma. Clin Cancer Res 2005;11:4295-304
   PubMed Web of Science ®Google Scholar
• Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/β-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008;14:471-84
   PubMed Web of Science ®Google Scholar
• López-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol 2009;40:783-94
   PubMed Web of Science ®Google Scholar
• Adesina AM, López-Terrada D, Wong KK, et al. Gene expression profiling reveals signatures characterizing subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol 2009;40:843-53
   PubMed Web of Science ®Google Scholar
• Tomlinson GE, Douglass EC, Pollock EH, et al. Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12–q21. Genes Chromosomes Cancer 2005;44:177-84
   PubMed Web of Science ®Google Scholar
• Weber RG, Pietsch T, von Schweinitz D, et al. Characterization of genomic alterations in hepatoblastomas. A role for gains on chromosomes 8q and 20 as predictors of poor outcome. Am J Pathol 2000;157:571-8
   PubMed Web of Science ®Google Scholar
• Terraciano LM, Bernasconi B, Ruck P, et al. Comparative genomic hybridization analysis of hepatoblastoma reveals high frequency of X-chromosome gains and similarities between epithelial and stromal components. Hum Pathol 2003;34:864-71
   PubMed Web of Science ®Google Scholar
• Schneider NR, Cooley LD, Finegold MJ, et al. The first recurring chromosome translocation in hepatoblastoma: Der(4)t(1;4)(q12;q34). Genes Chromosomes Cancer 1997;19:291-4
   PubMed Web of Science ®Google Scholar
• Parada LA, Limon J, Iliszko M, et al. Cytogenetics of hepatoblastoma: further characterization of 1q rearrangements by fluorescence in situ hybridization: an international collaborative study. Med Pediatr Oncol 2000;34:165-70
   PubMedGoogle Scholar
• Shim YH, Park HJ, Choi MS, et al. Hypermethylation of the p16 gene and lack of p16 expression in hepatoblastoma. Mod Pathol 2003;16:430-6
   PubMed Web of Science ®Google Scholar
• Honda S, Haruta M, Sugawara W, et al. The methylation status of RASSF1A promoter predicts responsiveness to chemotherapy and eventual cure in hepatoblastoma patients. Int J Cancer 2008;123:1117-25
   PubMed Web of Science ®Google Scholar
• Han J, Il Yeom Y. Specific gene transfer mediated by galactosylated poly-L-lysine into hepatoma cells. Int J Pharm 2000;202:151-60
   PubMedGoogle Scholar
• Aramaki Y, Lee I, Arima H, et al. Efficient gene transfer to hepatoblastoma cells through asialoglycoprotein receptor and expression under the control of the glycin A promoter. Biol Pharm Bull 2003;26:357-60
   PubMed Web of Science ®Google Scholar
• Yin C, Lin Y, Zhang X, et al. Differentiation therapy of hepatocellular carcinoma in mice with recombinant adenovirus carrying hepatocyte nuclear factor-4α gene. Hepatology 2008;48:1528-39
   PubMed Web of Science ®Google Scholar
• Aden D, Fogle A, Plotkin S, et al. Controlled synthesis of HBsAg in a differentiated human liver carcinoma-derived cell line. Nature 1979;282:615-6
   PubMed Web of Science ®Google Scholar
• Liu L, Cao Y, Chen C, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-8
   PubMed Web of Science ®Google Scholar
• Perugorria MJ, Castillo J, Latasa MU, et al. Wilms' tumor 1 gene expression in hepatocellular carcinoma promotes cell differentiation and resistance to chemotherapy. Cancer Res 2009;69:1358-67
   PubMed Web of Science ®Google Scholar
• Warmann SW, Fuchs J, Seitz G, et al. New trends in tumor biology: transfection of a human hepatoblastoma cell line with green fluorescent protein. J Pediatr Surg 2005;40:653-7
   PubMed Web of Science ®Google Scholar
• Warmann SW, Armeanu S, Frank H, et al. In vitro gene targeting in human hepatoblastoma. Pediatr Surg Int 2006;22:16-23
   PubMed Web of Science ®Google Scholar
• Warmann SW, Armeanu S, Heitmann H, et al. Optimizing vector application for gene transfer into human hepatoblastoma cells. Pediatr Surg Int 2006;22:733-42
   PubMed Web of Science ®Google Scholar
• Huang Z, Lei X, Zhong M, et al. Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. Acta Biochim Biophys Sin 2007;39:835-43
   Google Scholar
• Niedzielska G, Kocki J. Evaluation of bcl-2 expression in papilloma of larynx in children. Int J Pediatr Otorhinolaryngol 2000;53:25
   PubMed Web of Science ®Google Scholar
• Warmann SW, Frank H, Heitmann H, et al. Bcl-2 gene silencing in pediatric epithelial liver tumors. J Surg Res 2008;144:43-8
   PubMed Web of Science ®Google Scholar
• Feng LF, Zhong M, Lei XY, et al. Bcl-2 siRNA induced apoptosis and increased sensitivity to 5-fluorouracil and HCPT in HepG2 cells. J Drug Target 2006;14:21-6
   PubMed Web of Science ®Google Scholar
• Lin YC, You L, Xu Z, et al. Wnt inhibitory factor-1 gene transfer inhibits melanoma cell growth. Hum Gene Ther 2007;18:379-86
   PubMed Web of Science ®Google Scholar
• Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res 1997;57:461-5
   PubMed Web of Science ®Google Scholar
• Miller CR, Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/ 5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res 2002;62:773-80
   PubMed Web of Science ®Google Scholar
• Graepler F, Lemken ML, Wybranietz WA, et al. Bifunctional chimeric SuperCD suicide gene -YCD: YUPRT fusion is highly effective in a rat hepatoma model. World J Gastroenterol 2005;11:6910-9
   PubMed Web of Science ®Google Scholar
• Lal S, Lauer UM, Niethammer D, et al. Suicide genes: past, present and future perspectives. Immunol Today 2000;21:48-54
   PubMedGoogle Scholar
• Lemken ML, Graepler F, Wolf C, et al. Fusion of HSV-1 VP22 to a bifunctional chimeric SuperCD suicide gene compensates for low suicide gene transduction efficiencies. Int J Oncol 2007;30:1153-61
   PubMed Web of Science ®Google Scholar
• Warmann SW, Armeanu S, Heigoldt H, et al. Adenovirus-mediated cytosine deaminase/5-fluorocytosine suicide gene therapy of human hepatoblastoma in vitro. Pediatr Blood Cancer 2009;53:145-51
   PubMed Web of Science ®Google Scholar
• Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17
   PubMedGoogle Scholar
• Conzelmann KK. Genetic manipulation of non-segmented negative-strand RNA viruses. J Gen Virol 1996;77:381-9
   PubMed Web of Science ®Google Scholar
• Cattaneo R, Miest T, Shashkova EV, et al. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008;6:529-40
   PubMed Web of Science ®Google Scholar
• Chang JF, Chen PJ, Sze DY, et al. Oncolytic virotherapy for advanced liver tumors. J Cell Mol Med 2008: published online 23 Oct 2008, doi:10.1111/j.1582-4934.2008.00563.x
   Google Scholar
• Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009;9:64-71
   PubMed Web of Science ®Google Scholar
• Russell SJ, Peng KW. Measles virus for cancer therapy. Curr Top Microbiol Immunol 2009;330:213-41
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008;9:533-42
   PubMed Web of Science ®Google Scholar
• Liu TC, Hwang T, Park BH, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16:1637-42
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Armeanu S, Smirnow I, et al. Human precision-cut liver tumor slices as a tumor patient-individual predictive test system for oncolytic measles vaccine viruses. Int J Oncol 2009;34:1247-56
   PubMed Web of Science ®Google Scholar